The protective effect of simvastatin against low dose streptozotocin induced type 1 diabetes in mice is independent of inhibition of HMG-CoA reductase
Authors:
- Tobias RydgrenTRTobias Rydgren
- Stellan SandlerSSStellan Sandler
- 1 February 2009
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 379 (4) , 1076-1079
Abstract
No abstract availableKeywords
Funding Information
- Vetenskapsrådet (72X-08273)
- Novo Nordisk Fonden
This publication has 24 references indexed in Scilit:
- Simvastatin Protects against Multiple Low-Dose Streptozotocin-Induced Type 1 Diabetes in CD-1 Mice and Recurrence of Disease in Nonobese Diabetic MiceThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Assessment of the efficacy of different statins in murine collagen‐induced arthritisArthritis & Rheumatism, 2004
- Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling projectEuropean Heart Journal, 2002
- A new HMG‐CoA reductase inhibitor, rosuvastatin, exerts anti‐inflammatory effects on the microvascular endothelium: the role of mevalonic acidBritish Journal of Pharmacology, 2001
- Cerivastatin Suppresses Lipopolysaccharide-Induced ICAM-1 Expression through Inhibition of Rho GTPase in BAECBiochemical and Biophysical Research Communications, 2000
- Improvement of Nitric Oxide–Dependent Vasodilatation by HMG-CoA Reductase Inhibitors Through Attenuation of Endothelial Superoxide Anion FormationArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Insulin-dependent diabetes mellitus as a β-cell targeted disease of immunoregulationJournal of Autoimmunity, 1995
- Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH)JACC, 1995
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)The Lancet, 1994
- Prevention of Autoimmune Diabetes With Nonactivating Anti-CD3 Monoclonal AntibodyDiabetes, 1992